ESOC 2025 – presentation

Lys Therapeutics is proud to participate in the 11th European Stroke Organisation Conference (#ESOC2025) — the leading European forum for stroke research, innovation, and clinical advancement, in Helsinki, Finland, May 21-23.

🎤 Join us at Poster Session I, where our CEO & co-founder, Dr. Manuel Blanc, will present:

📍 Poster ID P447 – “LYS241: A Humanized Antibody Targeting Excitotoxicity and Blood-Brain Barrier Disruption in Ischemic Stroke”

📌 Session: Novel Targets / Experimental Findings to Clinical Translation

LYS241 is our lead monoclonal antibody designed to protect the brain by targeting both excitotoxicity and blood-brain barrier dysfunction — two key drivers of neuronal injury following stroke.

🩸 In the context of ischemic stroke, LYS241 also mitigates the off-target side effects of standard #thrombolytic agents (Roche & Boehringer Ingelheim #alteplase and #tenecteplase) on vascular endothelial cells, while enhancing blood #reperfusion, thereby improving their overall benefit-risk profile.

Looking forward to engaging with the international stroke community and advancing the conversation around next-generation #cytoprotective therapies.

#ESOC2025 #Stroke #Neuroscience #BBB #IschemicStroke #Cytoprotection #Neuroprotection #LYS241 #Biotech #TranslationalResearch #LysTherapeutics